Integra Lifesciences Analyst Ratings
Integra Lifesciences Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
10/26/2023 | 4.68% | Morgan Stanley | $44 → $37 | Maintains | Underweight |
08/24/2023 | 24.49% | Morgan Stanley | → $44 | Downgrades | Equal-Weight → Underweight |
07/28/2023 | 69.76% | JMP Securities | $65 → $60 | Maintains | Outperform |
07/19/2023 | 35.8% | Truist Securities | $44 → $48 | Maintains | Hold |
07/12/2023 | 49.95% | Jefferies | $58 → $53 | Upgrades | Hold → Buy |
06/08/2023 | — | Argus Research | Downgrades | Buy → Hold | |
05/31/2023 | 21.66% | Morgan Stanley | $59 → $43 | Maintains | Equal-Weight |
05/30/2023 | 24.49% | Truist Securities | $54 → $44 | Reiterates | Hold → Hold |
05/26/2023 | 83.9% | JMP Securities | → $65 | Reiterates | Market Outperform → Market Outperform |
05/24/2023 | 21.66% | JP Morgan | $56 → $43 | Downgrades | Neutral → Underweight |
05/23/2023 | 10.34% | Citigroup | $59 → $39 | Downgrades | Neutral → Sell |
05/18/2023 | 52.78% | Truist Securities | $58 → $54 | Maintains | Hold |
04/27/2023 | 83.9% | JMP Securities | $75 → $65 | Maintains | Outperform |
04/17/2023 | 75.41% | Truist Securities | $58 → $62 | Maintains | Hold |
02/23/2023 | 66.93% | Citigroup | $60 → $59 | Maintains | Neutral |
01/06/2023 | 66.93% | Morgan Stanley | $50 → $59 | Maintains | Equal-Weight |
12/20/2022 | 64.1% | Truist Securities | $52 → $58 | Maintains | Hold |
12/12/2022 | 69.76% | Citigroup | $50 → $60 | Maintains | Neutral |
10/27/2022 | 112.19% | JMP Securities | $85 → $75 | Maintains | Market Outperform |
10/27/2022 | 41.46% | Morgan Stanley | $49 → $50 | Maintains | Equal-Weight |
10/26/2022 | 47.12% | Truist Securities | $46 → $52 | Maintains | Hold |
10/17/2022 | 30.15% | Truist Securities | $60 → $46 | Maintains | Hold |
10/12/2022 | 35.8% | Jefferies | → $48 | Initiates Coverage On | → Hold |
10/11/2022 | 38.63% | Morgan Stanley | $58 → $49 | Maintains | Equal-Weight |
08/25/2022 | 64.1% | Morgan Stanley | $59 → $58 | Maintains | Equal-Weight |
07/25/2022 | 66.93% | Morgan Stanley | → $59 | Initiates Coverage On | → Equal-Weight |
07/20/2022 | 58.44% | Truist Securities | $70 → $56 | Maintains | Hold |
05/17/2022 | 89.56% | Citigroup | $70 → $67 | Maintains | Neutral |
01/18/2022 | 83.9% | B of A Securities | $55 → $65 | Maintains | Underperform |
12/17/2021 | 112.19% | JP Morgan | → $75 | Upgrades | Underweight → Neutral |
11/03/2021 | 146.15% | Credit Suisse | $84 → $87 | Maintains | Outperform |
09/15/2021 | — | BTIG | Downgrades | Buy → Neutral | |
02/19/2021 | 123.51% | Credit Suisse | $73 → $79 | Maintains | Outperform |
01/27/2021 | 126.34% | JMP Securities | $65 → $80 | Maintains | Market Outperform |
01/07/2021 | 106.54% | Credit Suisse | $60 → $73 | Maintains | Outperform |
10/29/2020 | 32.97% | Piper Sandler | $53 → $47 | Maintains | Neutral |
10/08/2020 | 41.46% | JP Morgan | → $50 | Downgrades | Neutral → Underweight |
08/12/2020 | 69.76% | Truist Securities | $55 → $60 | Maintains | Buy |
08/11/2020 | 49.95% | UBS | $51 → $53 | Maintains | Neutral |
08/11/2020 | 69.76% | Credit Suisse | $58 → $60 | Maintains | Outperform |
05/08/2020 | 55.61% | UBS | $65 → $55 | Maintains | Neutral |
05/08/2020 | 64.1% | Credit Suisse | $56 → $58 | Maintains | Outperform |
05/08/2020 | 83.9% | JMP Securities | $75 → $65 | Maintains | Market Outperform |
04/06/2020 | 30.15% | Wells Fargo | $62 → $46 | Maintains | Equal-Weight |
04/03/2020 | 55.61% | SunTrust Robinson Humphrey | → $55 | Initiates Coverage On | → Buy |
03/06/2020 | 83.9% | Credit Suisse | $70 → $65 | Maintains | Outperform |
02/20/2020 | 83.9% | UBS | $64 → $65 | Maintains | Neutral |
01/07/2020 | 64.1% | Piper Sandler | $59 → $58 | Downgrades | Overweight → Neutral |
12/18/2019 | 83.9% | UBS | $63 → $65 | Maintains | Neutral |
10/08/2019 | 83.9% | Wells Fargo | $68 → $65 | Maintains | Market Perform |
01/03/2019 | 58.44% | SunTrust Robinson Humphrey | → $56 | Initiates Coverage On | → Buy |
12/18/2018 | 61.27% | Credit Suisse | → $57 | Initiates Coverage On | → Outperform |
12/12/2018 | 61.27% | Credit Suisse | → $57 | Initiates Coverage On | → Outperform |
11/28/2018 | 64.1% | UBS | → $58 | Initiates Coverage On | → Neutral |
11/02/2018 | 69.76% | Citigroup | $66 → $60 | Maintains | Neutral |
11/02/2018 | 75.41% | JMP Securities | $66 → $62 | Maintains | Market Outperform |
11/01/2018 | 55.61% | Wells Fargo | $61 → $55 | Maintains | Market Perform |
11/01/2018 | 52.78% | Cantor Fitzgerald | $59 → $54 | Maintains | Neutral |
日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
---|---|---|---|---|---|
2023年10月26日 | 4.68% | 摩根士丹利 | $44→$37 | 维护 | 体重不足 |
2023年08月24日 | 24.49% | 摩根士丹利 | →$44 | 评级下调 | 等重→减码 |
07/28/2023 | 69.76% | JMP证券 | $65→$60 | 维护 | 跑赢大盘 |
07/19/2023 | 35.8% | Truist证券 | $44→$48 | 维护 | 保持 |
07/12/2023 | 49.95% | 杰富瑞 | $58→$53 | 升级 | 持有→购买 |
06/08/2023 | - | Argus研究 | 评级下调 | 购买→Hold | |
2023年05月31日 | 21.66% | 摩根士丹利 | $59→$43 | 维护 | 等重 |
2023年05月30日 | 24.49% | Truist证券 | $54→$44 | 重申 | 保持→保持 |
2023年05月26日 | 83.9% | JMP证券 | →$65 | 重申 | 市场表现优于→市场表现 |
2023年05月24日 | 21.66% | 摩根大通 | $56→$43 | 评级下调 | 中性→减持 |
2023年05月23日 | 10.34% | 花旗集团 | $59→$39 | 评级下调 | 中性→销售 |
2023年05月18日 | 52.78% | Truist证券 | $58→$54 | 维护 | 保持 |
04/27/2023 | 83.9% | JMP证券 | $75→$65 | 维护 | 跑赢大盘 |
04/17/2023 | 75.41% | Truist证券 | $58→$62 | 维护 | 保持 |
02/23/2023 | 66.93% | 花旗集团 | $60→$59 | 维护 | 中性 |
01/06/2023 | 66.93% | 摩根士丹利 | $50→$59 | 维护 | 等重 |
12/20/2022 | 64.1% | Truist证券 | $52→$58 | 维护 | 保持 |
2022年12月12日 | 69.76% | 花旗集团 | $50→$60 | 维护 | 中性 |
10/27/2022 | 112.19% | JMP证券 | $85→$75 | 维护 | 市场表现强于大盘 |
10/27/2022 | 41.46% | 摩根士丹利 | $49→$50 | 维护 | 等重 |
10/26/2022 | 47.12% | Truist证券 | $46→$52 | 维护 | 保持 |
10/17/2022 | 30.15% | Truist证券 | $60→$46 | 维护 | 保持 |
10/12/2022 | 35.8% | 杰富瑞 | →$48 | 开始承保 | →保留 |
2022年10月11日 | 38.63% | 摩根士丹利 | $58→$49 | 维护 | 等重 |
2022年08月25日 | 64.1% | 摩根士丹利 | $59→$58 | 维护 | 等重 |
07/25/2022 | 66.93% | 摩根士丹利 | →$59 | 开始承保 | →等重 |
07/20/2022 | 58.44% | Truist证券 | $70→$56 | 维护 | 保持 |
2022/05/17 | 89.56% | 花旗集团 | $70→$67 | 维护 | 中性 |
01/18/2022 | 83.9% | B of A证券 | $55→$65 | 维护 | 表现不佳 |
2021/12/17 | 112.19% | 摩根大通 | →$75 | 升级 | 减重→中性 |
11/03/2021 | 146.15% | 瑞士信贷 | $84→$87 | 维护 | 跑赢大盘 |
2021/09/15 | - | BTIG | 评级下调 | 购买→中性 | |
02/19/2021 | 123.51% | 瑞士信贷 | $73→$79 | 维护 | 跑赢大盘 |
2021/01/27 | 126.34% | JMP证券 | $65→$80 | 维护 | 市场表现强于大盘 |
01/07/2021 | 106.54% | 瑞士信贷 | $60→$73 | 维护 | 跑赢大盘 |
10/29/2020 | 32.97% | 派珀·桑德勒 | $53→$47 | 维护 | 中性 |
10/08/2020 | 41.46% | 摩根大通 | →$50 | 评级下调 | 中性→减持 |
2020年08月12日 | 69.76% | Truist证券 | $55→$60 | 维护 | 买 |
2020年08月11日 | 49.95% | 瑞银集团 | $51→$53 | 维护 | 中性 |
2020年08月11日 | 69.76% | 瑞士信贷 | $58→$60 | 维护 | 跑赢大盘 |
05/08/2020 | 55.61% | 瑞银集团 | $65→$55 | 维护 | 中性 |
05/08/2020 | 64.1% | 瑞士信贷 | $56→$58 | 维护 | 跑赢大盘 |
05/08/2020 | 83.9% | JMP证券 | $75→$65 | 维护 | 市场表现强于大盘 |
04/06/2020 | 30.15% | 富国银行 | $62→$46 | 维护 | 等重 |
04/03/2020 | 55.61% | SunTrust Robinson Humphrey | →$55 | 开始承保 | →购买 |
03/06/2020 | 83.9% | 瑞士信贷 | $70→$65 | 维护 | 跑赢大盘 |
02/20/2020 | 83.9% | 瑞银集团 | $64→$65 | 维护 | 中性 |
1/07/2020 | 64.1% | 派珀·桑德勒 | $59→$58 | 评级下调 | 超重→中性 |
2019年12月18日 | 83.9% | 瑞银集团 | $63→$65 | 维护 | 中性 |
2019年10月08日 | 83.9% | 富国银行 | $68→$65 | 维护 | 市场表现 |
2019年03月01日 | 58.44% | SunTrust Robinson Humphrey | →$56 | 开始承保 | →购买 |
2018年12月18日 | 61.27% | 瑞士信贷 | →$57 | 开始承保 | →跑赢大盘 |
2018年12月12日 | 61.27% | 瑞士信贷 | →$57 | 开始承保 | →跑赢大盘 |
2018年11月28日 | 64.1% | 瑞银集团 | →$58 | 开始承保 | →中性 |
11/02/2018 | 69.76% | 花旗集团 | $66→$60 | 维护 | 中性 |
11/02/2018 | 75.41% | JMP证券 | $66→$62 | 维护 | 市场表现强于大盘 |
2018/11/01 | 55.61% | 富国银行 | $61→$55 | 维护 | 市场表现 |
2018/11/01 | 52.78% | 康托·菲茨杰拉德 | $59→$54 | 维护 | 中性 |
What is the target price for Integra Lifesciences (IART)?
Integra Lifesciences(IART)的目标价格是多少?
The latest price target for Integra Lifesciences (NASDAQ: IART) was reported by Morgan Stanley on October 26, 2023. The analyst firm set a price target for $37.00 expecting IART to rise to within 12 months (a possible 4.68% upside). 20 analyst firms have reported ratings in the last year.
纳斯达克(Tmall:IART)2023年10月26日报道了INCELA LIFESSIONS的最新目标价。这家分析公司将目标价定为37.00美元,预计iart将在12个月内上涨(可能上涨4.68%)。去年,已有20家分析公司公布了评级。
What is the most recent analyst rating for Integra Lifesciences (IART)?
Integra生命科学(IART)的最新分析师评级是多少?
The latest analyst rating for Integra Lifesciences (NASDAQ: IART) was provided by Morgan Stanley, and Integra Lifesciences maintained their underweight rating.
纳斯达克(Sequoia Capital:IART)分析师对该公司的最新评级由摩根士丹利提供,该公司维持其减持评级。
When is the next analyst rating going to be posted or updated for Integra Lifesciences (IART)?
Integra Lifesciences(IART)的下一次分析师评级将于何时发布或更新?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Integra Lifesciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Integra Lifesciences was filed on October 26, 2023 so you should expect the next rating to be made available sometime around October 26, 2024.
分析师在进行了广泛的研究后得出了股票评级,其中包括查阅公共财务报表,与Integra Lifesciences的高管和客户交谈,以及收听收益电话会议。大多数分析师每三个月就会这样做一次,所以你每年应该会得到每家公司每家公司的4个评级。Integra生命科学的最后一次评级是在2023年10月26日提交的,所以你应该预计下一次评级将在2024年10月26日左右的某个时候提供。
Is the Analyst Rating Integra Lifesciences (IART) correct?
分析师对Integra Lifesciences(IART)的评级正确吗?
While ratings are subjective and will change, the latest Integra Lifesciences (IART) rating was a maintained with a price target of $44.00 to $37.00. The current price Integra Lifesciences (IART) is trading at is $35.35, which is out of the analyst's predicted range.
虽然评级是主观的,并将发生变化,但最新的Integra Lifesciences(IART)评级保持不变,目标价在44.00美元至37.00美元之间。Integra Lifesciences(IART)目前的交易价格为35.35美元,超出了分析师的预测区间。